Efficacy and Safety of Alirocumab and Evolocumab as Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) Inhibitors in Familial Hypercholesterolemia: A Systematic Review and Meta-Analysis

  • Авторы: Ghasempour G.1, Zamani-Garmsiri F.2, Shaikhnia F.3, Soleimani A.4, Hosseini Fard S.R.5, Leila J.6, Teimuri S.7, Parvaz N.8, Mohammadi P.9, Najafi M.10
  • Учреждения:
    1. Davee Department of Neurology, Feinberg School of Medicine,, Northwestern University
    2. Department of Clinical Biochemistry, Faculty of Medicine, Tehran University of Medical Sciences
    3. Department of Clinical Biochemistry, Faculty of Medicine, Uraemia University of Medical Sciences,
    4. Department of Clinical Biochemistry, School of Medicine, Tehran University of Medical Sciences
    5. Department of Clinical Biochemistry, Faculty of Medicine,, Tehran University of Medical Sciences
    6. Department of Biostatistics, School of Public Health, Iran University of Medical Sciences
    7. Institute of Cell Biology, University of Bern
    8. Department of Clinical Biochemistry, School of Medicine,, Iran University of Medical Sciences
    9. Davee Department of Neurology, Feinberg School of Medicine, Northwestern University,
    10. Department of Clinical Biochemistry, School of Medicine, Iran University of Medical Sciences
  • Выпуск: Том 31, № 2 (2024)
  • Страницы: 223-241
  • Раздел: Anti-Infectives and Infectious Diseases
  • URL: https://cijournal.ru/0929-8673/article/view/644632
  • DOI: https://doi.org/10.2174/0929867330666230228120601
  • ID: 644632

Цитировать

Полный текст

Аннотация

Background:Familial hypercholesterolemia (FH) is a prevalent and potentially fatal illness that causes a substantial elevation in low-density lipoprotein cholesterol (LDL-C).

Methods:A comprehensive search was done on PubMed/MEDLINE, EMBASE, Web of Science (WOS/ ISI), Scopus, ClinicalTrials (www.ClinicalTrials.gov), and conferences/ congress research papers. Random effect models were used to calculate mean differences (%) and risk ratios (RRs), and confidence intervals (95%).

Results:Ten studies (n=1489 patients) were included in this study. PCSK9 inhibitors decreased the levels of LDL-C by -49.59% (95%CI -55.5%, -43.67%) as compared to placebo. They also didn’t alter the Treatment-Emergent Adverse Event (TEAE) and neuronal events by RR 0.92 (0.75, 1.13) and 1.31 (0.66, 2.59), respectively. PCSK9 inhibitors were effective and safe in treating patients with FH.

Conclusion:There was high-quality evidence showing that monoclonal antibodies (alirocumab & evolocumab) lower LDL-C (GRADE: high), lipoprotein (a) (GRADE: High), triglycerides (TG) (GRADE: High), total cholesterol (GRADE: High), non-high-density lipoprotein cholesterol (non- HDL-C) (GRADE: Moderate), and apolipoprotein B (GRADE: High), and increase the HDL-C (GRADE: High) as well as apolipoprotein A1 (GRADE: High). Comparing PCSK9 inhibitors against placebo, neither TEAE (GRADE: high) nor neuronal events (GRADE: moderate) were changed.

Registration number:PROSPERO-CRD42022334035

Об авторах

Ghasem Ghasempour

Davee Department of Neurology, Feinberg School of Medicine,, Northwestern University

Email: info@benthamscience.net

Fahimeh Zamani-Garmsiri

Department of Clinical Biochemistry, Faculty of Medicine, Tehran University of Medical Sciences

Email: info@benthamscience.net

Farhad Shaikhnia

Department of Clinical Biochemistry, Faculty of Medicine, Uraemia University of Medical Sciences,

Email: info@benthamscience.net

Ali Soleimani

Department of Clinical Biochemistry, School of Medicine, Tehran University of Medical Sciences

Email: info@benthamscience.net

Syed Hosseini Fard

Department of Clinical Biochemistry, Faculty of Medicine,, Tehran University of Medical Sciences

Email: info@benthamscience.net

Janani Leila

Department of Biostatistics, School of Public Health, Iran University of Medical Sciences

Email: info@benthamscience.net

Shohreh Teimuri

Institute of Cell Biology, University of Bern

Email: info@benthamscience.net

Najmeh Parvaz

Department of Clinical Biochemistry, School of Medicine,, Iran University of Medical Sciences

Email: info@benthamscience.net

Payam Mohammadi

Davee Department of Neurology, Feinberg School of Medicine, Northwestern University,

Email: info@benthamscience.net

Mohammad Najafi

Department of Clinical Biochemistry, School of Medicine, Iran University of Medical Sciences

Автор, ответственный за переписку.
Email: info@benthamscience.net

Список литературы

  1. Pejic, R.N. Familial hypercholesterolemia. Ochsner J., 2014, 14(4), 669-672. PMID: 25598733
  2. Austin, M.A.; Hutter, C.M.; Zimmern, R.L.; Humphries, S.E. Genetic causes of monogenic heterozygous familial hypercholesterolemia: A HuGE prevalence review. Am. J. Epidemiol., 2004, 160(5), 407-420. doi: 10.1093/aje/kwh236 PMID: 15321837
  3. De Castro-Orós, I.; Pocoví, M.; Civeira, F. The genetic basis of familial hypercholesterolemia: Inheritance, linkage, and mutations. Appl. Clin. Genet., 2010, 3, 53-64. PMID: 23776352
  4. Softanmohammadi, E.; Piran, S.; Mohammadi, A.; Hosseni, B.; Naseri, F.; Shabani, M.; Najafi, M. Serum sdLDL-C and cellular SREBP2-dependent cholesterol levels; is there a challenge on targeting PCSK9? J. Med. Biochem., 2016, 35(4), 410-415. doi: 10.1515/jomb-2016-0019 PMID: 28670193
  5. Chen, P.; Chen, X.; Zhang, S. Current status of familial hypercholesterolemia in China: A need for patient FH registry systems. Front. Physiol., 2019, 10, 280. doi: 10.3389/fphys.2019.00280 PMID: 30949068
  6. Mytilinaiou, M.; Kyrou, I.; Khan, M.; Grammatopoulos, D.K.; Randeva, H.S. Familial hypercholesterolemia: New horizons for diagnosis and effective management. Front. Pharmacol., 2018, 9, 707. doi: 10.3389/fphar.2018.00707 PMID: 30050433
  7. Stone, N.J.; Robinson, J.G.; Lichtenstein, A.H.; Bairey Merz, C.N.; Blum, C.B.; Eckel, R.H.; Goldberg, A.C.; Gordon, D.; Levy, D.; Lloyd-Jones, D.M.; McBride, P.; Schwartz, J.S.; Shero, S.T.; Smith, S.C., Jr; Watson, K.; Wilson, P.W.F. 2013 ACC/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults: A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. J. Am. Coll. Cardiol., 2014, 63(25), 2889-2934. doi: 10.1016/j.jacc.2013.11.002 PMID: 24239923
  8. Kataoka, Y.; Puri, R.; Hammadah, M.; Duggal, B.; Uno, K.; Kapadia, S.R.; Tuzcu, E.M.; Nissen, S.E.; Nicholls, S.J. Frequency-domain optical coherence tomographic analysis of plaque microstructures at nonculprit narrowings in patients receiving potent statin therapy. Am. J. Cardiol., 2014, 114(4), 549-554. doi: 10.1016/j.amjcard.2014.05.035 PMID: 24996554
  9. Toth, P.P.; Harper, C.R.; Jacobson, T.A. Clinical characterization and molecular mechanisms of statin myopathy. Expert Rev. Cardiovasc. Ther., 2008, 6(7), 955-969. doi: 10.1586/14779072.6.7.955 PMID: 18666846
  10. Silva, M.A.; Swanson, A.C.; Gandhi, P.J.; Tataronis, G.R. Statin-related adverse events: A meta-analysis. Clin. Ther., 2006, 28(1), 26-35. doi: 10.1016/j.clinthera.2006.01.005 PMID: 16490577
  11. Navarese, E.P.; Szczesniak, A.; Kolodziejczak, M.; Gorny, B.; Kubica, J.; Suryapranata, H. Statins and risk of new-onset diabetes mellitus: Is there a rationale for individualized statin therapy? Am. J. Cardiovasc. Drugs, 2014, 14(2), 79-87. doi: 10.1007/s40256-013-0053-0 PMID: 24174174
  12. Blazing, MA; Giugliano, RP; Cannon, CP; Musliner, TA; Tershakovec, AM; White, JA Evaluating cardiovascular event reduction with ezetimibe as an adjunct to simvastatin in 18,144 patients after acute coronary syndromes: Final baseline characteristics of the IMPROVE-IT study population. Am Heart J, 2014, 168(2), 205-212. doi: 10.1016/j.ahj.2014.05.004 PMID: 25066560
  13. Norata, G.D.; Tavori, H.; Pirillo, A.; Fazio, S.; Catapano, A.L. Biology of proprotein convertase subtilisin kexin 9: beyond low-density lipoprotein cholesterol lowering. Cardiovasc. Res., 2016, 112(1), 429-442. doi: 10.1093/cvr/cvw194 PMID: 27496869
  14. Fu, T.; Guan, Y.; Xu, J.; Wang, Y. APP, APLP2 and LRP1 interact with PCSK9 but are not required for PCSK9-mediated degradation of the LDLR in vivo. Biochim. Biophys. Acta Mol. Cell Biol. Lipids, 2017, 1862(9), 883-889. doi: 10.1016/j.bbalip.2017.05.002 PMID: 28495363
  15. Nozue, T. Lipid lowering therapy and circulating PCSK9 concentration. J. Atheroscler. Thromb., 2017, 24(9), 895-907. doi: 10.5551/jat.RV17012 PMID: 28804094
  16. Manniello, M.; Pisano, M. Alirocumab (Praluent): First in the new class of PCSK9 inhibitors. P&T, 2016, 41(1), 28-53. PMID: 26766888
  17. Kasichayanula, S.; Grover, A.; Emery, M.G.; Gibbs, M.A.; Somaratne, R.; Wasserman, S.M.; Gibbs, J.P. Clinical pharmacokinetics and pharmacodynamics of evolocumab, a PCSK9 inhibitor. Clin. Pharmacokinet., 2018, 57(7), 769-779. doi: 10.1007/s40262-017-0620-7 PMID: 29353350
  18. Verhagen, A.P.; de Vet, H.C.W.; de Bie, R.A.; Kessels, A.G.H.; Boers, M.; Bouter, L.M.; Knipschild, P.G. The delphi list. J. Clin. Epidemiol., 1998, 51(12), 1235-1241. doi: 10.1016/S0895-4356(98)00131-0 PMID: 10086815
  19. Wan, X.; Wang, W.; Liu, J.; Tong, T. Estimating the sample mean and standard deviation from the sample size, median, range and/or interquartile range. BMC Med. Res. Methodol., 2014, 14(1), 135. doi: 10.1186/1471-2288-14-135 PMID: 25524443
  20. Barde, P.; Barde, M. What to use to express the variability of data: Standard deviation or standard error of mean? Perspect. Clin. Res., 2012, 3(3), 113-116. doi: 10.4103/2229-3485.100662 PMID: 23125963
  21. Egger, M.; Smith, G.D.; Schneider, M.; Minder, C. Bias in meta-analysis detected by a simple, graphical test. BMJ, 1997, 315(7109), 629-634. doi: 10.1136/bmj.315.7109.629 PMID: 9310563
  22. Duval, S. The trim and fill method. In: Publication bias in meta-analysis: Prevention, assessment and adjustments; , 2005; pp. 127-144. doi: 10.1002/0470870168.ch8
  23. Guyatt, G.H.; Oxman, A.D.; Kunz, R.; Vist, G.E.; Falck-Ytter, Y.; Schünemann, H.J. What is "quality of evidence" and why is it important to clinicians? BMJ, 2008, 336(7651), 995-998. doi: 10.1136/bmj.39490.551019.BE PMID: 18456631
  24. Blom, D.J.; Harada-Shiba, M.; Rubba, P.; Gaudet, D.; Kastelein, J.J.P.; Charng, M.J.; Pordy, R.; Donahue, S.; Ali, S.; Dong, Y.; Khilla, N.; Banerjee, P.; Baccara-Dinet, M.; Rosenson, R.S. Efficacy and safety of alirocumab in adults with homozygous familial hypercholesterolemia. J. Am. Coll. Cardiol., 2020, 76(2), 131-142. doi: 10.1016/j.jacc.2020.05.027 PMID: 32646561
  25. Ginsberg, H.N.; Rader, D.J.; Raal, F.J.; Guyton, J.R.; Baccara-Dinet, M.T.; Lorenzato, C.; Pordy, R.; Stroes, E. Efficacy and safety of alirocumab in patients with heterozygous familial hypercholesterolemia and LDL-C of 160 mg/dl or higher. Cardiovasc. Drugs Ther., 2016, 30(5), 473-483. doi: 10.1007/s10557-016-6685-y PMID: 27618825
  26. Kastelein, J.J.P.; Ginsberg, H.N.; Langslet, G.; Hovingh, G.K.; Ceska, R.; Dufour, R.; Blom, D.; Civeira, F.; Krempf, M.; Lorenzato, C.; Zhao, J.; Pordy, R.; Baccara-Dinet, M.T.; Gipe, D.A.; Geiger, M.J.; Farnier, M. ODYSSEY FH I and FH II: 78 week results with alirocumab treatment in 735 patients with heterozygous familial hypercholesterolaemia. Eur. Heart J., 2015, 36(43), ehv370. doi: 10.1093/eurheartj/ehv370 PMID: 26330422
  27. Moriarty, P.M.; Parhofer, K.G.; Babirak, S.P.; Cornier, M.A.; Duell, P.B.; Hohenstein, B.; Leebmann, J.; Ramlow, W.; Schettler, V.; Simha, V.; Steinhagen-Thiessen, E.; Thompson, P.D.; Vogt, A.; von Stritzky, B.; Du, Y.; Manvelian, G. Alirocumab in patients with heterozygous familial hypercholesterolaemia undergoing lipoprotein apheresis: The ODYSSEY ESCAPE trial. Eur. Heart J., 2016, 37(48), 3588-3595. doi: 10.1093/eurheartj/ehw388 PMID: 27572070
  28. Raal, F.; Scott, R.; Somaratne, R.; Bridges, I.; Li, G.; Wasserman, S.M.; Stein, E.A. Low-density lipoprotein cholesterol-lowering effects of AMG 145, a monoclonal antibody to proprotein convertase subtilisin/kexin type 9 serine protease in patients with heterozygous familial hypercholesterolemia: The Reduction of LDL-C with PCSK9 Inhibition in Heterozygous Familial Hypercholesterolemia Disorder (RUTHERFORD) randomized trial. Circulation, 2012, 126(20), 2408-2417. doi: 10.1161/CIRCULATIONAHA.112.144055 PMID: 23129602
  29. Raal, F.J.; Honarpour, N.; Blom, D.J.; Hovingh, G.K.; Xu, F.; Scott, R.; Wasserman, S.M.; Stein, E.A. Inhibition of PCSK9 with evolocumab in homozygous familial hypercholesterolaemia (TESLA Part B): A randomised, double-blind, placebo-controlled trial. Lancet, 2015, 385(9965), 341-350. doi: 10.1016/S0140-6736(14)61374-X PMID: 25282520
  30. Raal, F.J.; Stein, E.A.; Dufour, R.; Turner, T.; Civeira, F.; Burgess, L.; Langslet, G.; Scott, R.; Olsson, A.G.; Sullivan, D.; Hovingh, G.K.; Cariou, B.; Gouni-Berthold, I.; Somaratne, R.; Bridges, I.; Scott, R.; Wasserman, S.M.; Gaudet, D. PCSK9 inhibition with evolocumab (AMG 145) in heterozygous familial hypercholesterolaemia (RUTHERFORD-2): A randomised, double-blind, placebo-controlled trial. Lancet, 2015, 385(9965), 331-340. doi: 10.1016/S0140-6736(14)61399-4 PMID: 25282519
  31. Stein, E.A.; Gipe, D.; Bergeron, J.; Gaudet, D.; Weiss, R.; Dufour, R.; Wu, R.; Pordy, R. Effect of a monoclonal antibody to PCSK9, REGN727/SAR236553, to reduce low-density lipoprotein cholesterol in patients with heterozygous familial hypercholesterolaemia on stable statin dose with or without ezetimibe therapy: A phase 2 randomised controlled trial. Lancet, 2012, 380(9836), 29-36. doi: 10.1016/S0140-6736(12)60771-5 PMID: 22633824
  32. Guedeney, P.; Giustino, G.; Sorrentino, S.; Claessen, B.E.; Camaj, A.; Kalkman, D.N.; Vogel, B.; Sartori, S.; De Rosa, S.; Baber, U.; Indolfi, C.; Montalescot, G.; Dangas, G.D.; Rosenson, R.S.; Pocock, S.J.; Mehran, R. Efficacy and safety of alirocumab and evolocumab: A systematic review and meta-analysis of randomized controlled trials. Eur. Heart J., 2022, 43(7), e17-e25. doi: 10.1093/eurheartj/ehz430 PMID: 31270529
  33. Marais, A.D.; Blom, D.J.; Firth, J.C. Statins in homozygous familial hypercholesterolemia. Curr. Atheroscler. Rep., 2002, 4(1), 19-25. doi: 10.1007/s11883-002-0058-7 PMID: 11772418
  34. Gouni-Berthold, I.; Descamps, O.S.; Fraass, U.; Hartfield, E.; Allcott, K.; Dent, R.; März, W. Systematic review of published Phase 3 data on anti-PCSK9 monoclonal antibodies in patients with hypercholesterolaemia. Br. J. Clin. Pharmacol., 2016, 82(6), 1412-1443. doi: 10.1111/bcp.13066 PMID: 27478094
  35. McDonagh, M.; Peterson, K.; Holzhammer, B.; Fazio, S. A systematic review of PCSK9 inhibitors alirocumab and evolocumab. J. Manag. Care Spec. Pharm., 2016, 22(6), 641-653q. doi: 10.18553/jmcp.2016.22.6.641 PMID: 27231792
  36. Eslami, S.M.; Nikfar, S.; Ghasemi, M.; Abdollahi, M. Does evolocumab, as a PCSK9 inhibitor, ameliorate the lipid profile in familial hypercholesterolemia patients? A meta-analysis of randomized controlled trials. J. Pharm. Pharm. Sci., 2017, 20, 81-96. doi: 10.18433/J36C8N PMID: 28459663
  37. Li, C.; Lin, L.; Zhang, W.; Zhou, L.; Wang, H.; Luo, X.; Luo, H.; Cai, Y.; Zeng, C. Efficiency and safety of proprotein convertase subtilisin/kexin 9 monoclonal antibody on hypercholesterolemia: A meta-analysis of 20 randomized controlled trials. J. Am. Heart Assoc., 2015, 4(6), e001937. doi: 10.1161/JAHA.115.001937 PMID: 26077586
  38. Cao, Y.X.; Liu, H.H.; Li, S.; Li, J.J. A meta-analysis of the effect of PCSK9-monoclonal antibodies on circulating lipoprotein (a) levels. Am. J. Cardiovasc. Drugs, 2019, 19(1), 87-97. doi: 10.1007/s40256-018-0303-2 PMID: 30229525
  39. Dicembrini, I.; Giannini, S.; Ragghianti, B.; Mannucci, E.; Monami, M. Effects of PCSK9 inhibitors on LDL cholesterol, cardiovascular morbidity and all-cause mortality: A systematic review and meta-analysis of randomized controlled trials. J. Endocrinol. Invest., 2019, 42(9), 1029-1039. doi: 10.1007/s40618-019-01019-4 PMID: 30762200
  40. Karatasakis, A.; Danek, B.A.; Karacsonyi, J.; Rangan, B.V.; Roesle, M.K.; Knickelbine, T.; Miedema, M.D.; Khalili, H.; Ahmad, Z.; Abdullah, S.; Banerjee, S.; Brilakis, E.S. Effect of PCSK9 inhibitors on clinical outcomes in patients with hypercholesterolemia: A meta-analysis of 35 randomized controlled trials. J. Am. Heart Assoc., 2017, 6(12), e006910. doi: 10.1161/JAHA.117.006910 PMID: 29223954
  41. Schmidt, AF; Pearce, LS; Wilkins, JT; Overington, JP; Hingorani, AD; Casas, JP PCSK9 monoclonal antibodies for the primary and secondary prevention of cardiovascular disease. Cochrane Database Syst Rev, 2017, 4(4), CD011748. doi: 10.1002/14651858.CD011748.pub2
  42. Ge, X; Zhu, T; Zeng, H; Yu, X; Li, J; Xie, S A systematic review and meta-analysis of therapeutic efficacy and safety of alirocumab and evolocumab on familial hypercholesterolemia. Biomed Res Int., 2021, 2021, 8032978. doi: 10.1155/2021/8032978

Дополнительные файлы

Доп. файлы
Действие
1. JATS XML
Скачать

© Bentham Science Publishers, 2024